Condition 1: Atherosclerotic heart disease. Condition 2: Non-alcoholic fatty liver disease. Atherosclerotic heart disease of native coronary artery Fatty (change of) liver, not elsewhere classified
Conditions
Interventions
Intervention 1: Intervention group: Individuals in the intervention group will receive isocaloric low AGEs diet (based on dietary recommendations by Uribarrie et al.) for 12 weeks. The general recomme
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
50 Years to 70 Years
Inclusion criteria
Inclusion criteria: Age of 50 to 70 years BMI of 18.5 to 35 Kg/m2 Diagnosis of need for angioplasty treatment due to obstruction in one or two vessels
Exclusion criteria
Exclusion criteria: History of diabetes, thyroid disorders, chronic kidney diseases, autoimmune diseases, cancer History of myocardial infarction and stroke in the past 3 months Use of multi-vitamin, mineral, and antioxidant supplements over the past 3 months Follow of any weight loss diet or other special diets over the past year Familial hypercholesterolemia and hypertriglyceridemia History of well-known food allergy History of previous angioplasty Smoking, use of hubble-bubble and other drugs Ladies before menopause
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Carboxy methyl lysine. Timepoint: Before and after 12 weeks of intervention. Method of measurement: ELISA method.;High sensitive C-Reactive Protein (hs-CRP). Timepoint: Before and after 12 weeks of intervention. Method of measurement: ELISA method.;Tumor necrosis factor alpha (TNF-a). Timepoint: Before and after 12 weeks of intervention. Method of measurement: ELISA method.;Interleukin 6 (IL-6). Timepoint: Before and after 12 weeks of intervention. Method of measurement: ELISA method.;Vascular cell adhesion molecule 1 (VCAM-1). Timepoint: Before and after 12 weeks of intervention. Method of measurement: ELISA method.;Flow Mediated Dilation (FMD). Timepoint: Before and after 12 weeks of intervention. Method of measurement: Sonography.;Basal metabolism rate. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Bioelectrical Impedance Analysis (BIA).;Neuregulin 4 (NRG4). Timepoint: Before and after 12 weeks of intervention. Method of measurement: ELISA method.;Fibroblast growth factor 21 (FGF-21). Timepoint: Before and after 12 weeks of intervention. Method of measurement: ELISA method. | — |
Secondary
| Measure | Time frame |
|---|---|
| Appetite. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Visual analog scale.;Nesfatin. Timepoint: Before and after 12 weeks of intervention. Method of measurement: ELSA method.;Weight. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Weigher.;Waist circumference. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Meter.;Body composition. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Bioelectrical Impedance Analysis (BIA).;Serum lipid profile (total cholesterol, triglyceride, LDL and HDL). Timepoint: Before and after 12 weeks of intervention. Method of measurement: Enzymatic method.;Fasting Blood Sugar. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Enzymatic method.;Hemoglobin A1C. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Ion exchange chromatography.;Serum fasting insulin. Timepoint: Before and after 12 weeks of intervention. Method of measurement: ELISA method.;Omentin. Timepoint: Before and after 12 weeks of intervention. Method of measurement: ELISA method.;Insulin resistance. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Calculation based on HOMA-IR formula.;Fatty liver grade. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Sonography.;Hepatic enzymes (ALT and AST). Timepoint: Before and after 12 weeks of intervention. Method of measurement: Enzymatic method.;The amount of visceral adipose tissue in anterior to the aorta, posterior to the aorta and anterior to the liver. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Sonography.;Carotid intima-media thickness. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Sonography.;The amount of subcutaneous fat. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Sonography. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Javad Hossein Zadeh
Tehran University of Medical Sciences
Outcome results
None listed